GE Healthcare has debuted Serena Bright, a contrast-enhanced guided biopsy technology for use with mammography.
Serena Bright brings contrast-enhanced biopsy to mammography. Image courtesy of GE Healthcare.Working in conjunction with GE's SenoBright HD contrast-enhanced spectral mammography system, Serena Bright enables clinicians to conduct breast biopsy exams with contrast guidance using the same mammography equipment and with the same staff that's used to acquire screening or diagnostic mammograms, according to the vendor. Serena Bright highlights areas of unusual blood flow on these contrast-enhanced images in order to localize lesions that need to be biopsied, GE said.
After first showcasing Serena Bright at the 2019 RSNA meeting, GE received U.S. Food and Drug Administration (FDA) 510(k) clearance for Serena Bright in June. Jefferson Health is set to become the first healthcare system in the U.S. to offer this technology; the Philadelphia-based organization plans to begin offering Serena Bright to patients in late 2020, according to GE.
